Join Drs Nihar Desai and Neda Rasouli as they discuss the evolution of obesity treatment over the past two decades, including the latest novel therapies.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999845. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/38103820/

Obesity https://emedicine.medscape.com/article/123702-overview

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807920/

Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023 https://www.cdc.gov/nchs/products/databriefs/db508.htm

Physiology, Obesity Neurohormonal Appetite and Satiety Control https://www.ncbi.nlm.nih.gov/books/NBK555906/

Melanocortin-4 Receptor Complexity in Energy Homeostasis, Obesity and Drug Development Strategies https://pubmed.ncbi.nlm.nih.gov/34882941/

Bariatric Surgery https://emedicine.medscape.com/article/197081-overview

The Effects of Bariatric Surgery on Cardiovascular Outcomes and Cardiovascular Mortality: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/36909063/

Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics https://pubmed.ncbi.nlm.nih.gov/37758044/

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) https://clinicaltrials.gov/study/NCT05556512

Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/

Join Drs Nihar Desai and Seth Martin as they discuss low-density lipoprotein (LDL) cholesterol, dyslipidemia, and lipoprotein(a) for patients with cardiorenal metabolic syndrome.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999844. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) https://pubmed.ncbi.nlm.nih.gov/29263150/

Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/28304224/

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://pubmed.ncbi.nlm.nih.gov/36876740/

Two Phase 3 Trials of Inclisiran in Patients With Elevated LDL Cholesterol https://pubmed.ncbi.nlm.nih.gov/32187462/

Study of Heart and Renal Protection (SHARP): Randomized Trial to Assess the Effects of Lowering Low-Density Lipoprotein Cholesterol Among 9438 Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/21095263/

Cardiovascular Risk Reduction With Icosapent Ethyl for Hypertriglyceridemia https://pubmed.ncbi.nlm.nih.gov/30415628/

Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol https://pubmed.ncbi.nlm.nih.gov/35300814/

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/36342163/

Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement https://pubmed.ncbi.nlm.nih.gov/36036785/

A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/38565461/

Drs Nihar Desai, Andrew J. Sauer, and Matthew A. Sparks discuss novel therapies in cardiorenal metabolic syndrome, focusing in on the MRAs and potassium binders.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999843. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

The Kidney Failure Risk Equation: Evaluation of Novel Input Variables Including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts https://pubmed.ncbi.nlm.nih.gov/36857500/

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807924/

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/38490803/

Heart Failure in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/37763045/

Lokelma Prescribing Information https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/6de8f71b-d3af-4f76-9600-907c98616be6/6de8f71b-d3af-4f76-9600-907c98616be6_viewable_rendition__v.pdf

Sodium Zirconium Cyclosilicate in Hyperkalemia https://pubmed.ncbi.nlm.nih.gov/25415807/

Veltassa Prescribing Information https://veltassa.com/pi

Patiromer for the Management of Hyperkalemia in Heart Failure With Reduced Ejection Fraction: The DIAMOND Trial https://pubmed.ncbi.nlm.nih.gov/35900838/

Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics https://pubmed.ncbi.nlm.nih.gov/38878009/

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/33264825/

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial https://pubmed.ncbi.nlm.nih.gov/34775784/

Press Release: First Patient Enrolled in CARE-HK in HF to Evaluate Role of Veltassa® (Patiromer) in Enabling RAASi Treatment https://newsroom.csl.com/2021-04-28-First-patient-enrolled-in-CARE-HK-in-HF-to-evaluate-role-of-Veltassa-R-patiromer-in-enabling-RAASi-treatment

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry https://pubmed.ncbi.nlm.nih.gov/30025570/

Finerenone in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial https://pubmed.ncbi.nlm.nih.gov/38742248/

Additional Studies With Finerenone Across a Wide Range of Heart Failure Patients Initiated https://www.bayer.com/media/en-us/additional-studies-with-finerenone-across-a-wide-range-of-heart-failure-patients-initiated/

Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction — Results From the EMPULSE Trial https://pubmed.ncbi.nlm.nih.gov/38572654/

Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure (STRONG-HF): A Multinational, Open-Label, Randomised, Trial https://pubmed.ncbi.nlm.nih.gov/36356631/

Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs https://pubmed.ncbi.nlm.nih.gov/36328653/